0001567619-23-000625.txt : 20230106 0001567619-23-000625.hdr.sgml : 20230106 20230106161501 ACCESSION NUMBER: 0001567619-23-000625 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230106 DATE AS OF CHANGE: 20230106 EFFECTIVENESS DATE: 20230106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mytide Therapeutics, Inc. CENTRAL INDEX KEY: 0001905245 IRS NUMBER: 831051996 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-469965 FILM NUMBER: 23515233 BUSINESS ADDRESS: STREET 1: 451 D STREET SUITE 707 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (207) 659-4206 MAIL ADDRESS: STREET 1: 451 D STREET SUITE 707 CITY: BOSTON STATE: MA ZIP: 02210 D 1 primary_doc.xml X0708 D LIVE 0001905245 Mytide Therapeutics, Inc. 451 D STREET SUITE 707 BOSTON MA MASSACHUSETTS 02210 (207) 659-4206 DELAWARE None None Corporation true Dale Thomas 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Executive Officer Director Promoter Mr. Thomas is the President of the Issuer. Jason Norris 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Executive Officer Director Promoter Mr. Norris is the Treasurer and Secretary of the Issuer. Errik Anderson 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Director Biotechnology Decline to Disclose 06b false 2022-12-23 false true true Series A-3 Preferred Stock false 0 2500000 1164111 1335889 false 9 0 0 0 false Mytide Therapeutics, Inc. /s/ Dale Thomas Dale Thomas President of the Issuer 2023-01-06